2018
Mechanisms of resistance to HER2-targeted therapies in HER2-amplified uterine serous carcinoma, and strategies to overcome it.
Menderes G, Lopez S, Han C, Altwerger G, Gysler S, Varughese J, Schwartz PE, Santin AD. Mechanisms of resistance to HER2-targeted therapies in HER2-amplified uterine serous carcinoma, and strategies to overcome it. Discovery Medicine 2018, 26: 39-50. PMID: 30265854.Peer-Reviewed Original ResearchConceptsUterine serous carcinomaTyrosine kinase inhibitorsUSC patientsSerous carcinomaHER2/neu-targeted therapiesEndometrial cancer-related deathsHER2/neu amplificationKinase inhibitorsSingle-agent trastuzumabSignificant clinical activityRecent whole-exome sequencing studiesCancer-related deathEffective therapeutic strategyTumor growth inhibitionEndometrial cancerAggressive subtypeMechanisms of resistanceWhole-exome sequencing studiesClinical activityPreclinical studiesTarget therapyTherapeutic strategiesNeu amplificationHER2Therapy
1998
Radiation‐enhanced expression of E6/E7 transforming oncogenes of human papillomavirus‐16 in human cervical carcinoma
Santin A, Hermonat P, Ravaggi A, Chiriva‐Internati M, Pecorelli S, Parham G. Radiation‐enhanced expression of E6/E7 transforming oncogenes of human papillomavirus‐16 in human cervical carcinoma. Cancer 1998, 83: 2346-2352. PMID: 9840534, DOI: 10.1002/(sici)1097-0142(19981201)83:11<2346::aid-cncr14>3.0.co;2-g.Peer-Reviewed Original ResearchConceptsE6/E7 oncoproteinsMHC class ICervical carcinoma cell linesCarcinoma cell linesCervical carcinomaDose-dependent mannerE6/E7High dosesE7 oncoproteinsSiHa cell lineClass IRadiation therapyMajor histocompatibility complex restriction elementCell linesRadiation-induced drug resistanceHigh-risk HPV genotypesHPV-positive cervical carcinoma cell linesTumor cellsE6/E7 oncogenesE7 oncoprotein expressionE7 viral proteinsHuman papillomavirus infectionImportant risk factorTumor rejection antigensHuman papillomavirus 16